Background: Knowledge of melanoma presentations among pediatric and adolescent and young adult (AYA) patients are limited because of studies with small sample sizes.
Objective: The objective of this study was to determine the incidence trends and melanoma presentations based on age, sex, race, and ethnicity using a large cohort of diagnoses from 1997 to 2020.
Methods: A retrospective cohort study was completed using the National Childhood Cancer Registry from 1997 to 2020.
Results: Incidence rates were 1.74 (95% CI: 1.64-1.84) and 62.05 (95% CI: 61.6-62.5) per 1-million-person years for pediatric and AYA patients, respectively. Women encompassed 62.3% of the cohort. Non-Hispanic White patients represented 87.5% of all diagnoses, with significantly higher incidence rates of melanoma compared with all other racial and ethnic groups in both age groups, respectively (P < .001; P < .001). Superficial spreading was the most common of the specified histologic subtypes. The most common location in pediatric patients was the lower extremity, compared with trunk in AYA. There were statistically significant differences in the distributions of primary tumor location by sex, as well as by race and ethnicity, in both pediatric and AYA groups.
Limitations: Limitations in this study include retrospective data, selection, and miscoding from individual registries.
Conclusion: There are significant differences in tumor characteristics among pediatric and AYA patients with cutaneous melanoma. Trends in incidence rates are decreasing for young patients diagnosed with cutaneous melanoma.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jaad.2024.10.084 | DOI Listing |
JAMA Pediatr
January 2025
Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
Neurology
January 2025
The Dubowitz Neuromuscular Centre, Developmental Neurosciences Department, University College London, Great Ormond Street Institute of Child Health, United Kingdom.
Background And Objectives: Safety and efficacy of IV onasemnogene abeparvovec has been demonstrated for patients with spinal muscular atrophy (SMA) weighing <8.5 kg. SMART was the first clinical trial to evaluate onasemnogene abeparvovec for participants weighing 8.
View Article and Find Full Text PDFArch Dermatol Res
January 2025
Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, 1150 NW 14th Street, Miami, FL, 33136, USA.
Pityriasis rosea (PR) is an acute exanthematous disease with an uncertain physiopathology, increasingly recognized as potentially drug induced. This study aims to investigate medication triggers associated with PR by analyzing cases reported in the FDA Adverse Event Reporting System (FAERS) database. A retrospective review of 343 PR cases reported in the FAERS database from January 1, 1998, to March 31, 2024, was conducted.
View Article and Find Full Text PDFPsychooncology
January 2025
Department of Anesthesiology and Pain Medicine, University of Washington, Seattle, Washington, USA.
Background: Adolescents and young adults (AYA) with cancer experience long-term consequences into survivorship that impact quality of life, including mental health symptoms, substance use, and persistent pain. Given the elevated rates of pain, AYA cancer survivors are at increased risk for opioid pain medication (OPM) exposure, increasing risk for opioid-related negative consequences, particularly for those with mental health symptoms. Minimal research has documented that a considerable proportion of AYAs with cancer receive OPM that continues into survivorship, yet the lack of consensus on the definition of problematic opioid use coupled with the high clinical need for OPM makes it particularly challenging to understand the impact of OPM use in this population.
View Article and Find Full Text PDFEur J Neurol
January 2025
Department of Clinical and Experimental Epilepsy, UCL Queen Square Institute of Neurology, London, UK.
Objective: Temporal lobe epilepsy with hippocampal sclerosis (HS) is a surgically remediable syndrome. We determined temporal trends in the prevalence of hippocampal sclerosis surgeries and related factors.
Methods: We analysed a prospective cohort of adults who underwent epilepsy surgery at the NHNN, London, between 1990 and 2019.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!